Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer

Clinical Lung Cancer

Volumn 7, Issue 2, 2005, Pages 133-137

  Schuette, Wolfgang ^a   Nagel, Sylke ^a   Juergens, Stefan ^a   Bork, Ines ^b   Wollschlaeger, Bettina ^b   Schaedlich, Steffen ^a   Blankenburg, Thomas ^a  

^a City Hospital Martha Maria Halle Doelau   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Etoposide; Second line chemotherapy; Topotecan

Indexed keywords

ANTHRACYCLINE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; PLATINUM;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; DIARRHEA; DRUG RESPONSE; FEMALE; FEVER; HUMAN; INFORMED CONSENT; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; MYALGIA; NAUSEA AND VOMITING; NEUROPATHY; PAIN; PHASE 2 CLINICAL TRIAL; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT FAILURE;

EID: 32044459548     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2005.n.029     Document Type: Article

References (22)

1. Schuette W. Chemotherapy as treatment of primary and recurrent small cell lung cancer. Lung Cancer 2001; 33(suppl 1):S99-S107.
2. Niell HB, Beganovic S, Richey S, et al. The impact of dose per cycle of etoposide and cisplatin on outcomes in patients with extensive small-cell lung cancer. Clin Lung Cancer 2004;5:299-302.
3. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10:282-291.
4. Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997; 15:2090-2096.
5. Evolving role of topotecan in treating small-cell lung cancer [Research in Brief]. Clin Lung Cancer 2004; 5:270-272.
6. Schiller JH, Kim K, Hutson P, et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1996; 14:2345-2352.
7. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17:658-667.
8. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346:85-91.
9. DeVore RF, Blanke DV, Denham CA. Phase II study of irinotecan (CPT-11) in patients with previously treated small-cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1998; 17:451a (Abstract #1736).
10. Fisher MD, D'Orazio A. Irinotecan and cisplatin versus etoposide and cisplatin in small-cell lung cancer: JCOG 9511. Clin Lung Cancer 2000; 2:23-24.
11. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38:143-151.
12. Cormier Y, Eisenhauer E, Muldal A, et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1994; 5:283-285.
13. Van der Lee I, Postmus P, Smit E. The activity of gemcitabine in patients with resistant small cell lung cancer (SCLC); a phase II study. Proc Am Soc Clin Oncol 1999, 18:476a (Abstract #1835).
14. Masters GA, Declerck L, Blanke C, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group trial 1597. J Clin Oncol 2003; 21:1550-1555.
15. Bahadori HR, Rocha Lima CM, Green MR, et al. Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res 1999; 19:5423-5428.
16. Rocha Lima CM, Eckardt JR, Leong SS, et al. Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer. Semin Oncol 1999; 26:43-50.
17. Johnson DH, Greco FA, Strupp J, et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 1990; 8:1613-1617.
18. Shepherd FA, Evans WK, MacCormick R, et al. Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. Cancer Treat Rep 1987; 71:941-944.
19. Giaccone G, Ferrati P, Donadio M, et al. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 1987; 23:1697-1699.
20. Vincent M, Evans B, Smith I. First-line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother Pharmacol 1988; 21:45-48.
21. Le Chevalier T, Ibrahim N, Chomy P. A phase II study of irinotecan (CPT-11) in patients (pts) with small cell lung cancer (SCLC) progressing after initial response to first-line chemotherapy (CT). Proc Am Soc Clin Oncol 1997; 16:450a (Abstract #1617).
22. Survival, adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party. Respir Med 1989; 83:51-58.